Abstract: Objective To observe the expression of cytokeratin 19 (CK19), proliferating cell nuclear antigen (Ki67) and cytokeratin 7 (CK7) in primary hepatocellular carcinoma (HCC) tissues.Methods 65 patients with HCC hospitalized from March 2016 to March 2018 were selected as the research objects. The specimens of cancer tissue and adjacent normal tissue were taken during operation. The expressions of CK19, Ki67 and CK7 were measured by immunohistochemical staining. The positive rates of CK19, Ki67 and CK7 between cancer tissues and adjacent tissues were compared. The positive detection rates of CK19, Ki67 and CK7 in cancer tissues of HCC patients with different clinicopathological features were counted and compared. The 3-year survival of HCC patients with different expression levels of CK19, Ki67 and CK7 were analyzed.Results The positive rates of CK19, Ki67 and CK7 in cancer tissues were 40.00%, 73.85% and 70.77% respectively, which were significantly higher than those of 1.54%, 23.08% and 1.54% in adjacent tissues (χ²=29.216, 33.639, 67.483; P<0.05). The positive rates of CK19, Ki67 and CK7 were higher in HCC patients with TNM stage III~IV, poorly differentiated tissue, lymph node metastasis and capsule infiltration (P<0.05). The positive rates of CK7, CK19 and Ki67 in patients with lymph node metastasis and capsule infiltration were higher (P<0.05). The 3-year survival rates of CK19, Ki67 and CK7 positive HCC patients were 34.52%, 58.33% and 58.70% respectively, which were lower than those of 87.18%, 88.24% and 84.21% in negative HCC patients (Log-rank=19.250, 4.767, 3.910; P<0.05).Conclusion The expression levels of CK19, Ki67 and CK7 were highly correlated with TNM stage, tissue differentiation, lymph node metastasis and capsule infiltration, and have impact on the survival of HCC patients.

Key words: Cytokeratin 19, Proliferating cell nuclear antigen, Cytokeratin 7, Primary hepatocellular carcinoma